{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:05:51Z","timestamp":1788984351790,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Takeda Pharmaceutical Company Limited."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00380-024-02446-x","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T11:02:15Z","timestamp":1722337335000},"page":"100-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sex-based differences in left ventricular mass reduction across angiotensin II receptor blockers in patients with heart failure with preserved or mildly reduced ejection fraction"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4095-1567","authenticated-orcid":false,"given":"Masashi","family":"Amano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"2446_CR1","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145:e895\u2013e1032","journal-title":"Circulation"},{"key":"2446_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"2446_CR3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ejhf.807","volume":"19","author":"K Tsuji","year":"2017","unstructured":"Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H, CHART-2 Investigators (2017) Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19:1258\u20131269","journal-title":"Eur J Heart Fail"},{"key":"2446_CR4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, D\u00fcngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators Committees (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609\u20131620","journal-title":"N Engl J Med"},{"key":"2446_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Investigators (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461","journal-title":"N Engl J Med"},{"key":"2446_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators Committees (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777\u2013781","journal-title":"Lancet"},{"key":"2446_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","volume":"4","author":"IS Anand","year":"2011","unstructured":"Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569\u2013577","journal-title":"Circ Heart Fail"},{"key":"2446_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672\u2013678","journal-title":"Circulation"},{"key":"2446_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995\u20131003","journal-title":"Lancet"},{"key":"2446_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/01.CIR.0000083724.28630.C3","volume":"108","author":"PM Okin","year":"2003","unstructured":"Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations (2003) Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. Circulation 108:684\u2013690","journal-title":"Circulation"},{"key":"2446_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/sj.jhh.1001708","volume":"18","author":"JN Bella","year":"2004","unstructured":"Bella JN, Palmieri V, Wachtell K, Liu JE, Gerdts E, Nieminen MS, Koren MJ, Zabalgoitia M, Wright JT, Dahl\u00f6f B, Devereux RB (2004) Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. J Hum Hypertens 18:411\u2013416","journal-title":"J Hum Hypertens"},{"key":"2446_CR12","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.jacc.2003.12.051","volume":"43","author":"K Yasunari","year":"2004","unstructured":"Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A (2004) Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 43:2116\u20132123","journal-title":"J Am Coll Cardiol"},{"key":"2446_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/00005344-200311000-00007","volume":"42","author":"C Gaudio","year":"2003","unstructured":"Gaudio C, Ferri FM, Giovannini M, Pannarale G, Puddu PE, Vittore A, Fera MS, Vizza CD, Fedele F (2003) Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 42:622\u2013628","journal-title":"J Cardiovasc Pharmacol"},{"key":"2446_CR14","doi-asserted-by":"publisher","DOI":"10.15190\/d.2020.12","volume":"8","author":"SN Ahmed","year":"2020","unstructured":"Ahmed SN, Jhaj R, Sadasivam B, Joshi R (2020) Regression of the left ventricular hypertrophy in patients with essential hypertension on standard drug therapy. Discoveries (Craiova) 8:e115","journal-title":"Discoveries (Craiova)"},{"key":"2446_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0828-282X(08)70624-X","volume":"24","author":"DM Rabi","year":"2008","unstructured":"Rabi DM, Khan N, Vallee M, Hladunewich MA, Tobe SW, Pilote L (2008) Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol 24:491\u2013496","journal-title":"Can J Cardiol"},{"key":"2446_CR16","doi-asserted-by":"publisher","first-page":"F1136","DOI":"10.1152\/ajprenal.00677.2013","volume":"306","author":"MA Zimmerman","year":"2014","unstructured":"Zimmerman MA, Harris RA, Sullivan JC (2014) Female spontaneously hypertensive rats are more dependent on ANG (1\u20137) to mediate effects of low-dose AT1 receptor blockade than males. Am J Physiol Renal Physiol 306:F1136-1142","journal-title":"Am J Physiol Renal Physiol"},{"key":"2446_CR17","doi-asserted-by":"publisher","first-page":"12517","DOI":"10.1038\/s41598-023-39779-y","volume":"13","author":"S Ito","year":"2023","unstructured":"Ito S, Takahama H, Asakura M, Abe Y, Ajioka M, Anzai T, Arikawa T, Hayashi T, Higashino Y, Hiramitsu S, Iwahashi N, Izumi C, Kimura K, Kinugawa K, Kioka H, Lim YJ, Matsuoka K, Matsuoka S, Motoki H, Nakamura S, Nakayama T, Nomura A, Sasaoka T, Takiuchi S, Toyoda S, Ueda T, Watanabe T, Yamada A, Yamamoto M, Sozu T, Kitakaze M (2023) Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial. Sci Rep 13:12517","journal-title":"Sci Rep"},{"key":"2446_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10557-018-6799-5","volume":"32","author":"H Takahama","year":"2018","unstructured":"Takahama H, Asakura M, Abe Y, Ajioka M, Aonuma K, Anzai T, Hayashi T, Hiramitsu S, Kawai H, Kioka H, Kimura K, Lim YJ, Matsuoka K, Motoki H, Nagata Y, Nakamura S, Ohte N, Ozaki Y, Sasaoka T, Tamaki S, Hamasaki T, Kitakaze M, J-TASTE investigators (2018) Rationale and design of the multicenter trial on Japan Working Group on the effects of angiotensin receptor blockers selection (azilsartan vs. candesartan) on diastolic function in the patients suffering from heart failure with preserved ejection fraction: J-TASTE trial. Cardiovasc Drugs Ther 32:381\u2013388","journal-title":"Cardiovasc Drugs Ther"},{"key":"2446_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28:1-39.e14","journal-title":"J Am Soc Echocardiogr"},{"key":"2446_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/MBP.0000000000000042","volume":"19","author":"H Rakugi","year":"2014","unstructured":"Rakugi H, Kario K, Enya K, Sugiura K, Ikeda Y (2014) Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension. Blood Press Monit 19:164\u2013169","journal-title":"Blood Press Monit"},{"key":"2446_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3109\/08037051.2013.818758","volume":"22","author":"H Rakugi","year":"2013","unstructured":"Rakugi H, Kario K, Enya K, Igeta M, Ikeda Y (2013) Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. Blood Press 22:22\u201328","journal-title":"Blood Press"},{"key":"2446_CR22","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.2174\/1381612825666181203092918","volume":"24","author":"A Jekell","year":"2018","unstructured":"Jekell A, Nilsson PM, Kahan T (2018) Treatment of hypertensive left ventricular hypertrophy. Curr Pharm Des 24:4391\u20134396","journal-title":"Curr Pharm Des"},{"key":"2446_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/01.RES.73.3.413","volume":"73","author":"J Sadoshima","year":"1993","unstructured":"Sadoshima J, Izumo S (1993) Molecular characterization of angiotensin II\u2013induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73:413\u2013423","journal-title":"Circ Res"},{"key":"2446_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1136\/hrt.77.1.24","volume":"77","author":"H Schunkert","year":"1997","unstructured":"Schunkert H, Hense HW, Muscholl M, Luchner A, K\u00fcrzinger S, Danser AH, Riegger GA (1997) Associations between circulating components of the renin\u2013angiotensin\u2013aldosterone system and left ventricular mass. Heart 77:24\u201331","journal-title":"Heart"},{"key":"2446_CR25","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJM199606203342507","volume":"334","author":"TL Goodfriend","year":"1996","unstructured":"Goodfriend TL, Elliott ME, Catt KJ (1996) Angiotensin receptors and their antagonists. N Eng J Med 334:1649\u20131654","journal-title":"N Eng J Med"},{"key":"2446_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/jpet.110.176636","volume":"336","author":"M Ojima","year":"2011","unstructured":"Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H (2011) In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 336:801\u2013808","journal-title":"J Pharmacol Exp Ther"},{"key":"2446_CR27","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7461","volume":"7","author":"\u00c9 Walsh-Wilkinson","year":"2019","unstructured":"Walsh-Wilkinson \u00c9, Drolet MC, Le Houillier C, Roy \u00c8M, Arsenault M, Couet J (2019) Sex differences in the response to angiotensin II receptor blockade in a rat model of eccentric cardiac hypertrophy. PeerJ 7:e7461","journal-title":"PeerJ"},{"key":"2446_CR28","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1097\/HJH.0b013e32835731dd","volume":"30","author":"VU Viegas","year":"2012","unstructured":"Viegas VU, Liu ZZ, Nikitina T, Perlewitz A, Zavaritskaya O, Schlichting J, Persson PB, Regitz-Zagrosek V, Patzak A, Sendeski MM (2012) Angiotensin II type 2 receptor mediates sex differences in mice renal interlobar arteries response to angiotensin II. J Hypertens 30:1791\u20131798","journal-title":"J Hypertens"},{"key":"2446_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10557-005-5059-7","volume":"18","author":"M Nagai","year":"2004","unstructured":"Nagai M, Horikoshi K, Izumi T, Seki S, Taniguchi M, Taniguchi I, Mochizuki S (2004) Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 18:353\u2013362","journal-title":"Cardiovasc Drugs Ther"},{"key":"2446_CR30","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/ajh.2010.80","volume":"23","author":"SD Pierdomenico","year":"2010","unstructured":"Pierdomenico SD, Cuccurullo F (2010) Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens 23:876\u2013881","journal-title":"Am J Hypertens"},{"key":"2446_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.vph.2006.08.011","volume":"45","author":"A Mantovani","year":"2006","unstructured":"Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, Latini R (2006) The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 45:326\u2013330","journal-title":"Vascul Pharmacol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-024-02446-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:04:35Z","timestamp":1737990275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-024-02446-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2446"],"URL":"https:\/\/doi.org\/10.1007\/s00380-024-02446-x","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MA has nothing to disclose. CI reports personal fees from Daiichi Sankyo, Edwards Lifesciences, Bristol-Myers Squibb, Otsuka, Cannon Medical Systems, Sumitomo Dainippon, TOA EIYO, MSD, Pfizer, Boehringer Ingelheim, Teijin, Tsumura, and Novartis outside the submitted work. SI reports a grant from the Japan Society for the Promotion of Science outside the submitted work. MK reports grants from the Japanese government during the conduct of the study and the following outside the submitted work: grants from the Japanese government, grants from the Japan Heart Foundation, grants from the Japan Cardiovascular Research Foundation, grants and personal fees from Takeda, personal fees from Daiichi Sankyo, grants and personal fees from Pfizer, grants and personal fees from Ono, grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, grants from Novartis, grants and personal fees from Mitsubishi Tanabe, personal fees from Kowa, personal fees from Otsuka, grants from Sanofi, personal fees from Amgen, personal fees from Toyama-Kagaku, and grants and personal fees from Kureha.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}